InspireMD, Inc.

NasdaqCM:NSPR

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

⛓️ Blockchain

🛡 Defense & Military

🩺 Medical Instruments

💻 Telehealth

Location

Israel

Market Cap

USD 74.14 M

Share Price

USD 2.42

Avg Daily Volume

51,480

Change (1 day)

0.41%

Change (1 year)

-11.68%

Change (YTD)

-7.99%

InspireMD, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD -37.24 M

InspireMD, Inc. EBITDA is USD -37.24 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 55.62% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

InspireMD, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -23.93 M, a 30.01% change year over year.
InspireMD, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -18.41 M, a 16.96% change year over year.
InspireMD, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -15.74 M, a 35.05% change year over year.
InspireMD, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -11.65 M, a 36.56% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: NSPR

InspireMD, Inc.

CEO	Mr. Marvin L. Slosman
IPO Date	April 12, 2011
Location	Israel
Headquarters	4 Menorat Hamaor Street
Employees	85
Sector	🏥 Health Care
Industries Clinical Trials ⛓️ Blockchain 🛡 Defense & Military 🩺 Medical Instruments 💻 Telehealth

Description

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.